Omniab, Inc. (OABI) fundamentals score
OmniAb, Inc. licenses cutting-edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts.
Services-Commercial Physical & Biological Research · Industrials · Listed on NASDAQ
Overall: 5.7 out of 10, Mixed fundamentals
- Growth: 6.6/10
- Profitability: 3.3/10
- Financial health: 8.3/10
- Earnings quality: 6.3/10
- Valuation: 4.3/10
Scores are calculated from Omniab, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Industrials stocks
- Sezzle Inc. (SEZL): 9.1/10
- Paymentus Holdings, Inc. (PAY): 8.7/10
- Argan Inc. (AGX): 8.6/10
- Ferguson Enterprises Inc. (FERG): 8.6/10
- International Seaways, Inc. (INSW): 8.6/10
- Dorian Lpg Ltd. (LPG): 8.6/10
- Quinstreet, Inc. (QNST): 8.6/10
- Remitly Global, Inc. (RELY): 8.6/10